Two antibodies via the colon in healthy volunteers
Treatments studied
This study tests a new way of giving two antibodies through the colon (the large intestine). The antibodies are a type of medicine that may help treat diseases in the future. The study checks if this method is safe and how well the body absorbs the medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are in good general health with no significant medical problems.
- You are between 18 and 60 years old (assuming typical healthy volunteer range).
- Your weight is between 110 and 220 pounds (50 to 100 kg), and your body mass index is between 18 and 32.
- You have not been diagnosed with inflammatory bowel disease (like Crohn's or ulcerative colitis).
- You have no current or recent serious infections.
- You have no history of cancer, except for minor skin cancer that was removed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to see inflammation in the gut during a colonoscopy by using special dye attached to two IBD medications (adalimumab and risankizumab). The dye makes the medication glow under a special camera, which may help doctors see exactly where and how much inflammation is present, potentially guiding better treatment.
This study tests new long-acting antibodies, given alone or in combination, for people with moderate to severe ulcerative colitis. The goal is to see if these treatments can help reduce inflammation and improve symptoms.
This early-phase trial tests a new antibody-based therapy called SCTB10 in healthy volunteers to see if it's safe and how the body processes it. Participation can help determine the right dose for future patients.
This trial tests a new antibody drug called CM583 in healthy people to see if it is safe and how the body handles it. It may help treat conditions related to certain proteins involved in pain and inflammation.
This trial tests whether “treat-to-target” care—guided by regular symptom checks, telemonitoring, and patient education—works better than standard follow-up when starting adalimumab for ulcerative colitis. It aims to help control inflammation more effectively and reduce flare-ups.
This study tests a new drug called XmAb942 for people with moderate to severe ulcerative colitis. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments haven't worked well enough or caused side effects.
Hear when a new Healthy Subjects trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.